



1 (After amendment). A pyrazole derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof



62

A: benzene ring which may have one or more substituents; mono-, di- or tricyclic fused heteroaryl which may have one or more substituents; cycloalkyl which may have one or more substituents; a nitrogen-containing, saturated ring group which may have one or more substituents; lower alkenyl which may have one or more substituents; lower alkynyl which may have one or more substituents; or Alk which may have one or more substituents, or A and X may together form a group represented by a formula

Sub
A⁹



(wherein A² is a nitrogen-containing hetero ring selected from the group consisting of 1-pyrrolidinyl, pyrazolidinyl, piperidino, piperazinyl, morpholino, 3,4-dihydro-2H-1,4-benzoxazin-4-yl and indolinyl, wherein said hetero ring may have one or more substituents),

with the proviso that

(1) when D is 3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl, n is 0, B is 1,4-phenylene and X is NHCO, A is a group other than 4-methyl-1,2,3-thiadiazol-5-yl,

(2) when D is 1-methyl-5-trifluoromethyl-1H-pyrazol-3-yl, n is 0, B is thiophene-2,5-diyl and X is CONH, A is a group other than 4-chlorophenyl,

5Jh
A9
F 3 0 0 0 0 3 2 2 6 0

- (3) when D is 1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl, n is 0, B is thiophene-2,5-diyl and X is CONH, A is a group other than benzyl,
- (4) when D is 4-ethoxycarbonyl-5-trifluoromethyl-1H-pyrazol-1-yl, n is 0, B is 1,4-phenylene and Y is NHCO, A is a group other than trichlorovinyl,
- (5) when D is 1H-pyrazol-1-yl, n is 0, B is 1,4-phenylene and Y is NHCO, A is a group other than 2-ethoxyvinyl, and
- (6) when n is 1, D is 1H-pyrazol-5-yl substituted with at least one trifluoromethyl group or 1H-pyrazol-1-yl substituted with at least one trifluoromethyl group).

2. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein A is phenyl which may have one or more substituents of F group; mono-, di- or tricyclic fused heteroaryl which may have one or more substituents of F group; cycloalkyl which may have one or more substituents of F group; a nitrogen-containing, saturated ring group which may have one or more substituents of F group; lower alkenyl which may have one or more substituents of G group; lower alkynyl which may have one or more substituents of G group; or Alk which may have one or more substituents of G group, wherein the F group is a group consisting of -Alk, -lower alkenyl, -lower alkynyl, -Hal, -NH₂, -NH(Alk), -N(Alk)₂, -NO₂, -CN, -OH, -O-Alk, -O-CO-Alk, -SH, -S-Alk, -COOH, -COO-Alk, -CO-Alk, -CHO, -CONH₂, -CONH(Alk), -CON(Alk)₂, -SO-Alk, -SO₂-Alk, -SO₂NH₂, -SO₂NH-(Alk), -SO₂N(Alk)₂, -aryl, -cycloalkyl, -O-Alk-O-, -halogeno-lower alkyl, -Alk-NH₂, -Alk-NH(Alk), -Alk-N(Alk)₂, -Alk-OH, -Alk-O-Alk, -Alk-SH,


Sub
A9

$\frac{d}{dt} \left(\frac{\partial L}{\partial \dot{x}} \right) = \frac{\partial L}{\partial x}$

Hal; or Alk which may be substituted with one or more Hal, and

the F group is a group consisting of -Alk, -lower alkenyl, -lower alkynyl, -Hal, -NH₂, -NH(Alk), -N(Alk)₂, -NO₂, -CN, -OH, -O-Alk, -O-CO-Alk, -SH, -S-Alk, -COOH, -COO-Alk, -CO-Alk, -CHO, -CONH₂, -CONH(Alk), -CON(Alk)₂, -SO-Alk, -SO₂-Alk, -SO₂NH₂, -SO₂NH-(Alk) and -SO₂N(Alk)₂,

or A and X may together form a group represented by a formula



4 (after amendment). The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 3, wherein

n is 0, D is pyrazolyl which may have 1 to 3 substituents selected from -Alk, -halogeno-lower alkyl, -COOH and -COO-Alk,

B is phenylene or a monocyclic, divalent heteroaromatic ring group selected from the class consisting of thiophene, furan, thiazole, pyridine and pyrimidine, which may be substituted with Alk,

X is -NH-CO-, -N(OH)-CO-, -CO-NH-, -CH₂-NH- or -CO-N(Alk)-, and

A is phenyl which may have one or more substituents selected from the group consisting of -Alk, -Hal, -NH₂, -N(Alk)₂, -NO₂, -CN, -OH, -O-Alk and -COO-Alk; mono-

Sub
A9

di- or tricyclic fused heteroaryl selected from the group consisting of thienyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, tetrazolyl, triazolyl, thiadiazolyl, pyridyl, pyrazinyl and isoquinolyl, which may be substituted with Alk; cycloalkyl; lower alkenyl which may be substituted with one or more Hal; or Alk.

Sub
C2

5. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein D is pyrazolyl substituted with at least one trifluoromethyl group.

6. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein D is 1H-pyrazol-5-yl substituted with at least one trifluoromethyl group or 1H-pyrazol-1-yl substituted with at least one trifluoromethyl group.

7. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein X is -NH-CO- or -CO-NH-.

Sub
C3

8. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein D is 1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl and A is phenyl which may be substituted with Hal.


9. The pyrazole derivative or pharmaceutically acceptable salt thereof according to claim 1, wherein D is 3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl and A is monocyclic heteroaryl selected from the group consisting

Sub
C3

of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be substituted with Alk.

Sub
A10

10 (after amendment). A pharmaceutical composition which comprises a pyrazole derivative represented by the following general formula (I') or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier



(in the formula, each symbol has the following meaning;
D: pyrazolyl which may have 1 to 3 substituents selected from the group consisting of -Alk, -lower alkenyl, -lower alkynyl, -halogeno-lower alkyl, -Alk-cycloalkyl, -Alk-O-Alk, -cycloalkyl, -O-Alk, -COOH, -COO-Alk and -Hal,
n: 0 or 1,

B: phenylene, a nitrogen-containing, divalent, saturated ring group, or a monocyclic, divalent heteroaromatic ring group which may be substituted with Alk,

X: -NR¹-CR²R³-, -CR²R³-NR¹-, -NR¹-SO₂-, -SO₂-NR¹- or -CR⁴=CR⁵-,

R¹: -H, -OH, -Alk, -O-Alk or -CO-Alk,

R² and R³: the same or different from each other and each represents -H or -Alk, or R² and R³ together form =O or =S,

R⁴ and R⁵: the same or different from each other and each represents -H, -Hal, -halogeno-lower alkyl or -Alk, and

00773735-020004

Sub
A11

13. The pharmaceutical composition according to claim 12, which is a preventive or therapeutic agent for allergic, inflammatory or autoimmune diseases.

14. The pharmaceutical composition according to claim 13, which is a preventive or therapeutic agent for bronchial asthma or rheumatoid arthritis.

15. The pharmaceutical composition according to claims 10 to 14, wherein D is pyrazolyl substituted with at least one trifluoromethyl group.

16. The pharmaceutical composition according to claims 10 to 14, wherein D is 1H-pyrazol-5-yl substituted with at least one trifluoromethyl group or 1H-pyrazol-1-yl substituted with at least one trifluoromethyl group.

17. The pharmaceutical composition according to claims 10 to 14, wherein X is -NH-CO- or -CO-NH-.

18. The pharmaceutical composition according to claims 10 to 14, wherein D is 1-methyl-3-trifluoromethyl-1H-pyrazol-5-yl and A is phenyl which may be substituted with Hal.

19. The pharmaceutical composition according to claims 10 to 14, wherein D is 3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl and A is monocyclic heteroaryl selected from the group consisting of thiazolyl, thiadiazolyl, thienyl and pyridyl, which may be substituted with Alk.

add
A12

add
B2